Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28564319 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL125692 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL29112129 | 0.95 | — | — | |
| Methane SCHEMBL4096245 | 0.95 | — | — | |
| SCHEMBL27912512 | 0.94 | MAPK1 (0.31) | — | |
| SCHEMBL7240952 | 0.94 | — | — | |
| SCHEMBL1296 | 0.94 | — | — | |
| SCHEMBL1331944 | 0.94 | — | — | |
| SCHEMBL10940023 | 0.94 | — | — | |
| Water SCHEMBL2929026 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117164586-B | Preparation method of spiro diamine | 苏州凯瑞医药科技有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-117164586-A | Preparation method of spiro diamine | 苏州凯瑞医药科技有限公司 | 2023-12-05 | — | — | CN | claimed |
| CN-110678455-B | Novel crystalline solid compounds of 3-phenyl-4-propyl-1- (pyridin-2-yl) -1H-pyrazol-5-ol hydrochloride | 阿普塔生物治疗公司 | 2022-08-16 | — | — | CN | claimed |
| EP-3613733-B1 | NOVEL CRYSTALLINE SOLID COMPOUND OF 3-PHENYL-4-PROPYL-1-(PYRIDIN-2-YL)-1H-PYRAZOL-5-OL HYDROCHLORIDE | APTABIO THERAPEUTICS INC (KR) | 2022-07-20 | — | — | EP | claimed |
| US-11174240-B2 | Crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol hydrochloride | APTABIO THERAPEUTICS INC. (KR) | 2021-11-16 | — | — | US | claimed |
| CN-112724117-A | Refining method of doxepin hydrochloride | 南京济群医药科技股份有限公司 | 2021-04-30 | — | — | CN | claimed |
| US-20210122726-A1 | NOVEL CRYSTALLINE SOLID COMPOUND OF 3-PHENYL-4-PROPYL-1-(PYRIDIN-2-YL)-1H-PYRAZOL-5-OL HYDROCHLORIDE | APTABIO THERAPEUTICS INC. (KR) | 2021-04-29 | — | — | US | claimed |
| EP-3613733-A1 | NOVEL CRYSTALLINE SOLID COMPOUND OF 3-PHENYL-4-PROPYL-1-(PYRIDIN-2-YL)-1H-PYRAZOL-5-OL HYDROCHLORIDE | Aptabio Therapeutics Inc. (KR) | 2020-02-26 | — | — | EP | claimed |
| CN-110678455-A | Novel crystalline solid compounds of 3-phenyl-4-propyl-1- (pyridin-2-yl) -1H-pyrazol-5-ol hydrochloride | 阿普塔生物治疗公司 | 2020-01-10 | — | — | CN | claimed |
| EP-3551612-A1 | PROCESS FOR THE PREPARATION OF N-(4-(6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S)-HYDROXYBUTANEDIOATE AND ITS POLYMORPHS THEREOF | MSN Laboratories Private Limited, R&D Center (IN) | 2019-10-16 | — | — | EP | claimed |
| WO-2018104954-A1 | PROCESS FOR THE PREPARATION OF N-(4-(6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S)-HYDROXYBUTANEDIOATE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2018-06-14 | — | — | WO | claimed |
| WO-2013111161-A2 | PROCESS FOR THE PREPARATION OF 3-ARYL-2-METHYL-PROPANAMINE DERIVATIVES AND POLYMORPHS THEREOF | MSN LABORATORIES LIMITED (IN) | 2013-08-01 | — | — | WO | claimed |
| CN-101602734-B | Method for preparing Erlotinib hydrochloride crystal form A | ZHEJIANG JIUZHOU PHARM CO LTD | 2011-07-20 | — | — | CN | claimed |
| CN-101602734-A | A kind of preparation method of Erlotinib hydrochloride crystal form A | ZHEJIANG JIUZHOU PHARMACEUTICA (CN) | 2009-12-16 | — | — | CN | claimed |
| WO-2009034582-A2 | PROCESS FOR THE PREPARATION OF AMORPHOUS FEXOFENADINE HYDROCHLORIDE | IND-SWIFT LABORATORIES LIMITED (IN) | 2009-03-19 | — | — | WO | claimed |
| US-20040229914-A1 | Novel crystalline form-VI of donepezil hydrochloride and process for the preparation thereof | DR. REDDY'S LABORATORIES LIMITED | 2004-11-18 | — | — | US | claimed |
| US-20250145591-A1 | INHIBITORS OF ADVANCED GLYCATION END PRODUCTS | PRAETEGO INC | 2025-05-08 | — | — | US | disclosed |
| US-20250101000-A1 | INHIBITORS OF ADVANCED GLYCATION END PRODUCTS | PRAETEGO INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-3951958-A | VAGINOTROPIC | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3932388-A | STEROIDS, GLUCOCORTICOID ACITIVITY | SCHERING CORPORATION (US) | 1976-01-13 | — | — | US | disclosed |